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INTRODUCTION 
 
Cell senescence and stress modulate the proliferative 
potential of mammalian cells, suggesting that both are 
capable of suppressing the formation of tumors [1-7].  
Stresses and dysfunction of the telomeric 
DNA/telomerase complex can trigger senescence. 
Impaired telomere function activates the canonical 
DNA damage response pathway that engages p53 to 
initiate apoptosis or replicative senescence, while the 
inactivation of the tumor suppressor genes (Rb and p53) 
allowing cells to escape senescence [8-16]. The 
resulting cell immortalization is an essential component 
of the tumorigenic phenotype of human cancer cells [8-
12, 17]. 
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Abstract: P53 homolog p63 was shown to play a role in premature ageing phenotype found in mouse models through
regulation of the replicative senescence.  We previously showed that the forced ΔNp63α expression decreased the SIRT1
protein  levels,  and  induced  the  replicative  senescence  of  human  keratinocytes,  while  the  ectopic  SIRT1  expression
decreased  the  senescence.  Using  the  ΔNp63α  overexpressing  and  p63‐/+  heterozygous  mice,  we  found  that  ΔNp63α
induced the mTERT promoter activation through the down regulation of the SIRT1 protein levels, inactivation of p53
deacetylation,  decrease  of  the  p53/Sp1  protein‐protein  interaction,  and  the  overall  induction  of  mTERT  transcription
regulation. In the same time, by a forming of protein‐protein complexes with the ABBP1, ΔNp63α induced the mTERT RNA
splicing leading to an increasing expression of spliced mTERT isoforms playing a role of dominant‐negative inhibitors of
mTERT activity and therefore decreasing the levels of TERT activity in mouse epidermal keratinocytes. The overall effect of
the ΔNp63α overexpression resulted in decrease in telomerase activity and increase in replicative senescence observed in
mouse keratinocytes.  This dual molecular mechanism of telomerase regulation might underline the previously shown
effect of ΔNp63α on premature ageing phenotype.
Skin epidermis is one of the few regenerative tissues 
that express telomerase, the ribonucleoprotein complex 
that can counteract telomere erosion, one of the 
presently mostly favored potential mechanisms causing 
cellular ageing [18].  Altered functioning of both 
telomerase and telomere-interacting proteins is present 
in some human premature ageing syndromes and in 
cancer, and recent findings indicate that alterations that 
affect telomeres at the level of chromatin structure 
might also have a role in human disease [18-24]. 
 
P53 transcriptional factors are involved in regulation of 
cellular senescence and organismal ageing [14, 16, 25-
30].  While p53 suppresses the onset of malignancy and, 
thereby extends lifespan, it induces cellular senescence 
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Transgenic mouse strains (p53+/m) expressing the C-
terminal p53 fragment along with the wild type p53 
display an early onset of phenotypes associated with 
ageing [30].  The ΔN-isoform of p53 recently reported 
[27, 28] or ΔN-isoforms of p63 and p73 (all lacking the 
transactivation domain) might modulate an imbalance 
between them and full-length p53 leading to an altered 
transcriptional function of p53 and in turn to an 
acceleration of the ageing process [30, 31].    
   
Sirtuins possessing the histone deacetylase activity are 
implicated in the extension of lifespan of eukaryotic 
cells [29, 32-40].  Epigenetic alterations of the 
expression of longevity genes by changing the 
level/pattern of histone acetylation may be an important 
factor in determining the longevity of animals [41, 42].  
SIRT1 encodes an NAD-dependent histone deacetylase 
that playing a critical role in transcriptional silencing 
[39, 40].  Studies have implicated SIRT1 in binding to 
and deacetylating of the p53 protein (or Forkhead 
family members), inhibiting p53-dependent apoptosis, 
preventing a premature cellular senescence and leading 
to increase of organismal longevity [43, 44].  
 
We previously showed an important role for p53 
homolog p63 (ΔNp63α), shown to be a key switch in 
skin renewal [25, 45], in regulation of ageing process in 
p53+/m and ΔNp63α transgenic mouse models [29, 
30].  P63 was also shown to transcriptionally regulate 
many genes implicated in epithelial integrity, 
differentiation, and ageing [31].  
 
RESULTS 
 
ΔNp63α induces the SIRT1 degradation and the 
p53/SIRT1 protein interaction 
 
Mice overexpressing a truncated mutant of p53 
(p53+/m, C-terminal part) or ΔNp63α were shown to 
exhibit a premature ageing of skin and shortened life 
span suggesting that these mice share a common 
molecular mechanism underlying these phenotypes [29, 
30].  The link between cellular senescence/premature 
ageing and p53 family members was reported by several 
groups [25, 26, 29, 30].  P63 deficiency was found to 
induce cellular senescence and to cause an accelerated 
ageing phenotype in adult mice showing the conditional 
expression or depletion in stratified epithelia 
contributed to ageing [29, 30]. We have previously 
shown the expression of endogenous ΔNp63α in the 
p53+/m mice and overexpression of ΔNp63α in 
transgenic mice may play an important role in 
premature ageing [29]. We also found that the 
formation of ΔNp63α/SIRT1 complexes led to a 
decreased SIRT1 levels in both ΔNp63α transgenic and 
p53+/m mice [29].  We further observed that the 
marked senescence in the ΔNp63α overexpressing cells 
that could be modulated by a forced expression of 
SIRT1 [29].  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. ΔNp63α mediates the SIRT1 degradation and
p53  deacetylation.  (A)  The  proteasome‐dependent  degra‐
dation of SIRT1. (B) The deacetylation of p53. (C) The protein
complex  formation  between  p53,  SIRT1  and  Sp1.  Mice  with
heterozygous  p63‐/+  and  ΔNp63α  transgenic  expression  were
sources  for  epidermal  keratinocytes  [29,  45].  Total  lysates
(2x10
5  cells)  were  used  for  immunoblotting  with  indicated
antibodies (dilutions: anti‐ΔNp63, 1:500; anti‐SIRT1, 1:300; anti‐
β‐actin, 1:400; anti‐p53, 1:500; anti‐acetyl‐p53, 1:400; anti‐Sp1,
1:300).  Cells were also treated with the proteasome inhibitor,
MG‐132  (20  μg/ml)  for  24  h  before  lysis.  For  immuno‐
precipitation  (IP)  experiments,  we  used  total  lysates  obtained
from 1x10
6 cells/500 μl and anti‐p53 antibodies (10 μg/500μl).
Blots  were  quantitatively  scanned  using  the  PhosphorImager
and  all  of  the  data  (mean  +SD)  were  from  at  least  three
independent experiments. 
For these studies, we used primary mouse epidermal 
keratinocytes obtained from mice with p63-/+ 
heterozygous inactivation [45] and the ΔNp63α 
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Using the primary mouse epidermal cell culture, we 
found that the protein levels of SIRT1 were 
significantly lower (by 9-fold) in cells obtained from the 
ΔNp63α transgenic mice (0.06+0.01) than in the cells 
prepared from p63-/+ mice (0.55+0.07, Fig. 1A).  We 
further found that the 26S proteasome inhibitor, MG-
132, dramatically modulated the SIRT1 protein 
degradation effect, which was likely to be induced by 
ΔNp63α dramatically increasing the SIRT protein levels 
(Fig. 1A).  We also showed that levels of acetylated p53 
were much greater (by 4- fold) in the ΔNp63α 
transgenic mice (0.49+0.06) than in p63-/+ mice 
(0.12+0.02), while the p53 protein levels were 
practically unaffected (Fig. 1B). Next, we observed that 
the protein complex formation between p53, SIRT1 and 
Sp1 dramatically decreased in the ΔNp63α transgenic 
mice compared to p63-/+ mice (Fig. 1D).  
 
ΔNp63α activates the transcription regulation of 
TERT core promoter 
 
The 3′-region of the core TERT promoter contains a 
GC-box, which binds Sp1 and is essential for 
transactivation and expression of the full-length 
telomerase [43, 48-54].  Overexpression of Sp1 leads to 
a significant activation of transcription in a cell type-
specific manner, while an interaction with p53 could 
eliminate the binding of Sp1, resulting in TERT 
repression [43]. To further examine this phenomenon, 
we used the inhibitor/RNA silencing approach to 
investigate the effect of the inhibition of SIRT1, p53 
and Sp1 function on the transcriptional regulation of 
mouse telomerase-reverse transcriptase (mTERT) 
promoter. The epidermal cells form p63-/+ mice and 
the  ΔNp63α transgenic mice were transfected with 
shRNA for SIRT1, p53 and Sp1 or incubated with 
SIRT1 inhibitor, Sirtinol, as described elsewhere [36-
38]. We, therefore, found that the SIRT1 expression led 
to a decrease of acetylated p53, while both Sirtinol and 
SIRT1 shRNA induced an increase of acetylated p53 
(Fig. 2A). We further studied the effect of these 
treatments on luciferase reporter activity driven by Sp1 
binding element of the mTERT promoter [53, 54].   
Mouse keratinocytes transfected with shRNA for 
SIRT1, p53 and Sp1 or treated with Sirtinol were also 
co-transfected with the murine core TERT promoter-
Luc reporter vector (pGL3-347-Luc) containing the Sp1 
binding site along with the Renilla luciferase plasmid as 
described elsewhere (Methods).  We showed that the 
overexpression of ΔNp63α results in a significant 
increase in transcriptional activity of the core mTERT 
promoter (Fig. 2B, samples 1 and 6).  We also observed 
that inhibition of SIRT1 expression or function, and p53 
expression led to an increase of luciferase reporter 
activity, while silencing of Sp1 induced the down 
regulation of luciferase reporter activity (Fig. 2B).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure  2.  ShRNA  silencing  of  ΔNp63‐SIRT1‐p53‐Sp1
pathway.  Mouse  epidermal  keratinocytes  (2x10
5  cells)  from
p63‐/+ (samples 1‐5) or overexpressing ΔNp63α (samples 6‐10)
were  treated  with  control  media  (samples  1  and  6),  SIRT1
inhibitor  (Sirtinol,  100  μg/ml  for  24  h;  samples  2  and  7),  or
transfected with the SIRT1 shRNA (samples 3 and 8), p53 shRNA
(samples 4 and 9), and sh‐Sp1 RNA (samples 5 and 10).  (A)
Immunoblotting  with  indicated  antibodies  (dilutions:  anti‐
ΔNp63,  1:500;  anti‐SIRT1,  1:300;  anti‐Sp1,  1:300;  anti‐p53,
1:500; anti‐acetyl‐p53, 1:400; anti‐β‐actin, 1:400). The vertical
lines separate data obtained from independent protein gels. (B)
mTERT  promoter  luciferase  reporter  assay.  Mouse
keratinocytes (1.0 x 10
5) were transfected with the pGL3‐347‐
Luc plasmid (0.5 μg) or the pGL3 control plasmid (0.5 μg) by
using FuGENE6 transfection reagent (Roche Diagnostics). 3 ng
of the pRL‐SV40 (Promega) was used as a normalization control.
Measurements were  performed  by  using  the Dual  Luciferase
reporter  assay  system  (Promega)  and  a  BioOrbit  1251
luminometer.  The  activity  of  each  TERT  promoter  fragment
was expressed as a relative value. All of the data (mean +SD)
were from at least three independent experiments. 
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treatments affect endogenous transcriptional regulation 
of mTERT promoter using the chromatin 
immunoprecipitation (ChIP) approach using an 
antibody against Sp1 as described elsewhere [53, 54].  
We thus found that ΔNp63α overexpression induced an 
interaction of Sp1 transcription factor with the core 
promoter of mTERT (Fig. 3).  Similar effect was found 
in cells transfected with shRNA inhibiting SIRT1 or 
p53 expression, or in cells incubated with Sirtinol (100 
μg/ml for 24 h). These results suggested that both 
SIRT1 and p53 functions play a critical role in 
transcription inhibition of the core mTERT promoter.  
 
 
 
 
 
 
 
 
 
 
 
ΔNp63α modulates the RNA splicing of mTERT 
 
We have previously shown that ΔNp63α is implicated 
in both transcriptional regulation and post-trans-
criptional processing/splicing of downstream target 
genes [31, 55].   We previously reported that the ΔNp63α 
protein physically associated with ABBP1, one of the 
key components of RNA processing molecular 
machinery [55]. We found that the ΔNp63α ABBP1 
protein complexes contributed into the fibroblast growth 
factor receptor 2 receptor RNA splicing leading to 
epithelial-mesenchymal transition [55].  Here we report 
that these ΔNp63α ABBP1 protein complexes were also 
involved in the post-transcriptional regulation of 
mTERT.  
 
Telomerase is a reverse transcriptase that adds telomeric 
repeats d(TTAGGG)n to chromosomal ends [56].   In 
most normal somatic cells, telomerase is repressed and 
telomeres progressively shorten, leading to limited 
proliferative lifespan [2, 56].  Telomerase reactivation is 
associated with cellular immortalization and is a fre-
quent event during tumorigenesis [2, 11, 13].  Structu-
rally telomerase is a ribonucleoprotein complex that 
consists of two essential components, TERT and a 
template RNA, TR [56].  Telomerase ribonucleoprotein 
complex plays a critical role in ageing, tumorigenesis, 
immortalization and “stemness” phenotype [2, 11, 13, 
20, 23, 24, 57].  A number of reports pointed-out that a 
major control mechanism underlying the telomerase 
function lies at the level of transcription and alternative 
splicing of TERT [18, 42, 48, 49, 51, 53, 59-62].  
 
We thus investigated whether the overexpression of the 
ΔNp63α protein would affect the RNA splicing of 
mTERT and mTR in mouse epidermal cells.  First, we 
observed that the ΔNp63α overexpression led to an 
increasing level of the ΔNp63α ABBP1 protein 
complexes (by 3-4-fold, Fig. 4A). Second, we found 
that the ΔNp63α overexpression failed to affect 
expression of RNA component of telomerase complex 
(mTR) as shown in Figure 4B (middle panel).  And 
finally, we found that the ΔNp63α overexpression 
dramatically induced the levels of α-splice isoform (by 
5-6-fold) and β-splice isoform (by 1.5-2-fold) of 
mTERT (Fig. 4B, upper panel and Fig. 4C), while 
levels of the full-length isoform of mTERT remained 
unchanged in mouse epidermal keratinocytes from the 
ΔNp63α transgenic mice compared to such levels found 
in cells from p63-/+ mice (Fig. 4B, upper panel).  As 
previously reported, these variants were not equal in 
their ability to generate an active TERT complex [63-
66].   Telomerase activity is only provided by the full-
length TERT [63-66].  The smaller splice variants (α 
and β) are inactive and may act as dominant-negative 
inhibitors for telomerase activity [63-66].   The α-splice 
isoform lacks a 12-residue region of the conserved 
reverse transcriptase motif A (in-frame deletion), and 
the β-splice is missing a 182 bp-region resulting in a 
non-sense mutation leading to premature stop codon, 
truncating the protein before the conserved reverse 
transcriptase motifs B, C, and D [63-66]. 
Figure 3. ΔNp63α modulates binding of Sp1 to Sp1 DNA‐
binding region by decreasing the SIRT1 protein levels and
deacetylation of p53.  Chromatin immunoprecipitation assay
(X‐ChIP). Mouse epidermal keratinocytes (5x10
7 cells) expressing
heterozygous p63‐/+ (samples 1‐5) and overexpressing ΔNp63α
(samples 6‐10) were treated with control media (samples 1 and
6), SIRT1 inhibitor (Sirtinol, 100 μg/ml for 24 h; samples 2 and 7),
SIRT1 shRNA (samples 3 and 8), p53 shRNA (samples 4 and 9),
and shSp1 RNA (samples 5 and 10). The protein‐DNA complexes
were precipitated with a primary antibody for Sp1. As negative
controls, we used immunoglobulins (IgG) from rabbit (IgG‐R) or 
mouse (IgG‐M) sera. The mTERT‐derived Sp1 promoter region
using  the  following  primers:  sense  (SP1),  5’‐
CTCACTGTCTGTGCAACCACAGCAGCTG‐3’  (position‐363),  and
antisense  (AP2),  5’‐AGAGCACCGCGGGGCAACGAGGAGCGCG‐3’
(position +143) giving raise to a 506 bp PCR product. The PCR 
products  were  run  on  2%  agarose  gels  and  visualized  by
ethidium bromide staining.  
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ΔNp63α modulates telomerase activity and 
increases cellular senescence 
 
To further examine the effect of the ΔNp63α 
overexpression on the overall telomerase activity, we 
obtained the mouse epidermal keratinocytes from the 
ΔNp63α transgenic mice and p63-/- heterozygous mice. 
Cells were transfected with shRNA against SIRT1, p53 
or Sp1 for 72 h or treated with Sirtinol for 24 h. 
Resulting cells were tested for telomerase activity using 
the TRAP assay, as described elsewhere [63-66].  We 
first found that the level of telomerase activity in 
keratinocytes from p63+/- mice is significantly greater 
than in cells from the ΔNp63α transgenic mice (Fig. 5A, 
samples 1 and 6). Second, we observed that the 
treatment with either SIRT1 inhibitor or shRNA against 
SIRT or p53 led to an increase in telomerase activity in 
keratinocytes from p63+/- mice (Fig. 5A, samples 2-4), 
while no significant changes were seen in the ΔNp63α 
transgenic mice (Fig. 5A, samples 7-9). Third, we 
showed that the Sp1 shRNA dramatically decreased the 
telomerase activity in both mouse models (Fig. 5A, 
samples 5 and 10).    
 
 
 
 
Figure 4. ΔNp63α increases levels of the mTERT‐spliced 
isoforms  via  protein  interaction  with  ABBP1.  Mouse 
epidermal  keratinocytes  (2x10
6  cells)  expressing  heterozygous
p63‐/+  and  ΔNp63α  transgene.  (A)  Cells  were  tested  for  the
levels  of  ΔNp63α  and  ABBP1  by  immunoblotting  and
ABBP1ΔNp63α  protein  complexes  using  immunoprecipitation
(IP) with an antibody to ABBP1 followed by immunoblotting with
an antibody to ΔNp63α. As a control, the protein level of β‐actin 
was monitored. (B) Cells were examined for the expression of
the mTERT and mTR transcripts using RT‐PCR. GAPDH was used
in RT‐PCR assay, as a control.  (C) The relative expression of TERT
and TR was quantitatively analyzed and plotted as bars using the
Microsoft Excel software. All of the data (mean +SD) were from
at  least  three  independent  experiments.  Samples:  cells  from
p63‐/+  mice,  1‐  TERT/GAPDH  ratio;  2‐  TR/GAPDH  ratio;  cells
from  the  ΔNp63α  transgenic  mice,  3‐  TERT/GAPDH  ratio;  4‐
TR/GAPDH ratio. PCR experiments with the 2164/ 2620 set of
primers generated three products that represent the full‐length 
TERT transcript (457 bp), the α‐splice transcript (421 bp), and
the β‐splice transcript (275 bp). Sequence analysis revealed that 
the  longer  transcripts  were  full‐length  one  and  the  shorter
transcripts were α and β‐ spliced messages of mTERT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  ΔNp63α overexpression modulated the overall 
telomerase  activity  and  induced  a  S‐β‐gal  activity.  The 
mouse keratinocytes from the p63‐/+ mice (samples 1, 3, 5, 7, 9) 
and  ΔNp63α  transgenic  mice  (samples  2,  4,  6,  8,  10)  were
treated with the control media (samples 1 and 2) or Sirtinol (100 
μg/ml  for  24h,  samples  3  and  4)  or  transfected  for  72h  with 
shRNA against SIRT1 (samples 5 and 6), p53 (samples 7 and 8) 
and Sp1 (samples 9 and 10). (A) Telomerase activity. Telomerase 
activity was determined by the TRAP assay using 1 µg of protein 
extract  obtained  from  2x10
5  cells.  Quantitative  analysis  was 
done using Molecular Dynamics densitometer and ImageQuant 
software. The intensity of the positive control lane was taken as 
100%. The experiment was repeated three times, and error bars 
represent mean ± S.D.  (B) S‐β‐gal activity. The S‐β‐gal activity
was measured using a senescence kit.    
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resulting in telomere shortening was shown to lead to a 
replicative senescence [11-22].  We previously showed 
that the forced overexpression of ΔNp63α led to an 
increase in replicative senescence of human squamous 
cell carcinoma cells that were distinguished by the 
presence of a biomarker - senescence-associated β-
galactosidase (S-β-gal) as described [29]. Senescent 
cells show a series of morphological and physiological 
alterations including a flat and enlarged morphology, an 
increase in acidic S-β-gal activity, chromatin 
condensation, and changes in gene expression pattern. 
Here we observed that the level of the S-β-gal activity 
in keratinocytes from p63+/- mice is significantly lower 
than in cells from the ΔNp63α transgenic mice (Fig. 5B, 
samples 1 and 6).  Then, we showed that the treatment 
with either Sirtinol or SIRT shRNA or p53 shRNA led 
to a decrease in the S-β-gal activity in keratinocytes 
from p63-/+ mice (Fig. 5B, samples 2-4). Finally, we 
found that the Sp1 shRNA dramatically increased the S-
β-gal activity in p63-/+ mice (Fig. 5B, sample 5).  In the 
same time, epidermal keratinocytes obtained from the 
ΔNp63α transgenic mice failed to display significant 
changes in the S-β-gal activity under above-mentioned 
experimental conditions (Fig. 5B, samples 7-10). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
Normal somatic cells undergo a limited number of 
divisions before entering an irreversible growth-arrest 
state, a replicative cellular senescence, providing a 
barrier against the unlimited proliferation and formation 
of cancer [1-7].  The molecular mechanism underlying 
the replicative senescence involves the telomere 
shortening due to the inability to renew the telomere 
length by a telomerase enzymatic complex [56]. 
Telomeres are specific DNA-protein complexes present 
at the ends of linear chromosomes, which protect the 
latter from degradation and fusion/recombination [56]. 
Telomeric DNA is synthesized by a multisubunit 
enzymatic complex, telomerase, consisting of the 
telomerase reverse transcriptase (TERT), an RNA 
component (TR) acting as a template, and other 
associated proteins [56].  Replicative senescence can be 
overcome by overexpression of the catalytic subunit of 
telomerase-reverse transcriptase (TERT) as previously 
reported [59]. A growing number of reports showed that 
various treatments could induce premature senescent 
phenotype through regulation of TERT [3, 5, 8, 10, 15, 
25, 52, 57]. They include various types of DNA 
damage, overexpression of oncogenes or mitogenic 
signals, and changes affecting chromatin structure [3, 5, 
8, 10, 15, 25, 52, 57].   Replicative senescence is likely 
to play a role in ageing of highly proliferative tissues 
such as skin, endothelium and lymphoid tissues [18, 60, 
62, 64].  
 
Telomerase activity closely correlates with the 
expression of TERT, which could potentially be 
regulated at the transcriptional (promoter) and post-
transcriptional (splicing) levels [2].  The TERT 
promoter activity is usually regulated by a variety of 
transcription factors (AP-1, c-Myc, Sp1, Sp3, NF-kB, 
Ets, and the estrogen receptor), and by chromatin 
remodeling and epigenetic methylation mechanisms [3, 
5, 8, 10, 15, 25, 48, 52, 57].   Several variants of TERT 
are also generated by RNA splicing within the reverse 
transcriptase region and the C-terminal part of the 
TERT gene and shown to function as endogenous 
dominant-negative regulators/inhibitors of telomerase 
activity [63-66].  Cells from skin cancers (melanomas) 
were shown to produce the complete TERT mRNA 
along with one or more alternatively spliced transcripts 
[62].  Depending of ratio between the full-length TERT 
and spliced TERT isoforms, melanoma cells were 
characterized as positive and negative for telomerase 
activity [48, 62].  The high abundance of spliced TERT 
isoforms dramatically inhibited the overall telomerase 
activity [62]. 
Figure 6. Schematic representation of regulation of TERT
transcription  and  splicing  by  ΔNp63α.  (A)  mTERT
transcription. (B) mTERT splicing. 
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p53+/m and ΔNp63α mice was accompanied by 
increased  ΔNp63α expression leading to induced 
cellular senescence that was rescued by SIRT1 
suggesting that ΔNp63α levels may affect ageing 
through regulation of SIRT1 [29].  Modulation of p63 
function through genetic knockdown/RNA silencing 
[25, 26] or by dominant-negative inhibitor, ΔNp63α 
[29], could lead to a premature ageing phenotype, 
however implicating SIRT1 regulation into the 
molecular mechanism underlying the organismal ageing 
process [29, 32-40]. 
  
In the current report, we showed that from the first 
hand, ΔNp63α induced the mTERT promoter activation 
through the down regulation of the SIRT1 protein 
levels, inactivation of p53 deacetylation, decrease of the 
p53/Sp1 protein-protein complexes, and the overall 
induction of mTERT transcription regulation (Fig. 6A). 
From the other hand, by a forming of protein-protein 
complexes with the ABBP1-derived RNA 
processing/splicing complex (Fig. 6B), ΔNp63α 
induced the mTERT RNA splicing leading to an 
increasing expression of spliced mTERT isoforms 
playing a role of dominant-negative inhibitors of 
mTERT activity and therefore decreasing the levels of 
TERT activity in mouse epidermal keratinocytes 
overexpressing the ΔNp63α protein. The overall effect 
of the ΔNp63α overexpression resulted in decrease in 
telomerase activity and increase in replicative 
senescence observed in mouse keratinocytes.  This dual 
molecular mechanism of telomerase regulation might 
underline the previously shown effect of p63 (ΔNp63α) 
on premature ageing phenotype observed in mice 
overexpressing the ΔNp63α protein. 
  
METHODS 
 
Antibodies and reagents. We used a rabbit polyclonal 
antibody to ABBP1 (raised against the C-terminal 
peptide SQRRGGHQNNYKPY by Affinity Bio-
Reagents), a goat polyclonal antibody to ΔNp63 (N-16, 
sc-8609), and a mouse monoclonal antibody to p63 
(4A4, sc-8431, both from Santa Cruz Biotechnology), a 
mouse monoclonal antibody to SIRT1 (#07-131, 
Upstate Cell Signaling Solutions), and a rabbit 
polyclonal antibody to mouse Sp1 (#S9809, Sigma) or a 
rabbit polyclonal ChIP-grade antibody against Sp1 
(Upstate Biotechnology). We also used an agarose-
conjugated p53 monoclonal antibody (Ab-6; Oncogene 
Research Products), and anti-acetylated-Lys382 p53 
antibody (Cell Signaling Technology). We also used the 
SIRT1 inhibitor, Sirtinol (#566320-5MG), and a 26S 
proteasome inhibitor, MG-132 (474791-1MG) that were 
purchased from Calbiochem. 
 
Preparation of mouse keratinocytes.  P63-/+ mice 
harboring the p63Brdm2 allele (obtained from Jackson 
Laboratories) and ΔNp63α transgenic mice (generated 
in our laboratory) were used [29, 45] according to the 
regulations of the Johns Hopkins University Animal 
Care and Use Committee (JHUACUC).  Primary 
keratinocytes were isolated from 3-4 day-old newborn 
pups by a trypsinization [46, 47].    Cells were plated at 
3 x 10
6 cells per 60-mm dish in chelex-treated low-
calcium EMEM medium, BioWhittaker) supplemented 
with 8% fetal bovine serum and 0.05 mM calcium) and 
grown at 37
oC with 5% CO2.  Total lysates were 
obtained from cells flash-frozen in liquid N2 and 
transferred into a buffer A as described [55]. The 
samples were homogenized on ice and centrifuged at 
15,000 x g for 20 min at 4°C.  The supernatants were 
separated on 12.5% SDS-PAGE gels and probed with 
indicated antibodies.  Immunoblotting and immuno-
precipitation was performed as described [55].  
 
TERT promoter luciferase assay. The mouse TERT 
promoter  region  encompassing  Sp1 binding  element   
(-347 to +1) was kindly obtained from Drs. Charles 
Giardina and Rashimi R. Joshi, University of 
Connecticut, Sparks, CT) as previously described [53, 
54].  For the luciferase assay, mouse keratinocytes (1.0 
x 105) were transfected with the pGL3-347-Luc 
plasmid (0.5 μg) or the pGL3 control plasmid (0.5 μg) 
by using FuGENE6 transfection reagent (Roche 
Diagnostics). 3 ng of the pRL-SV40 (Promega) was 
used as a normalization control. Cell lysates were 
obtained and measurements were performed by using 
the Dual Luciferase reporter assay system (Promega) 
and a BioOrbit 1251 luminometer.  The activity of each 
TERT promoter fragment was expressed as a relative 
value. All of the data (mean +SD) were from at least 
three independent experiments. 
 
Small hairpin RNA (shRNA), design and manipulation. 
ShRNA for mouse SIRT1 (#TR505485), Sp1 
(#TR502115) and p53 (#TG500002) and scrambled 
shRNA were purchased from Origene Technologies and 
used according to the manufacturer's recommendations. 
Control and experimental shRNA (200 pmol/six-well 
plate) were transiently introduced into mouse 
keratinocytes with aid of TurboFectin 8.0 (Origene 
Technologies), and 72 h later, total lysates were used 
for immunoblotting.  
 
Telomerase activity assay. For telomerase activity 
detection, we used the PCR-mediated telomere repeat 
amplification protocol (TRAP) as previously described 
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substituted for lysis buffer.  Two μl of cell lysate 
(protein concentration 0.5 μg/μl) were used per assay.  
The PCR products were run on a 10% polyacrylamide 
gel, stained with SYBR Green (BioWhittaker Molecular 
Applications), and detected using the Typhoon system 
(Molecular Dynamics). For quantitative analysis, the 
ImageQuant version 5.2 software (Molecular Dyna-
mics) was used. The area of integration of all peaks was 
normalized to the signal from the internal standard, 
then, after background subtraction, expressed relative to 
the positive control signal (100 cell equivalent) that was 
run with each experiment. The comparison of mean 
values between the different groups was evaluated by 
ANOVA with Fisher's LSD test. 
 
RT-PCR assay. Total RNA was isolated from cells 
using Trizol reagent (Invitrogen). One μg of total RNA 
was used to generate a cDNA from each sample using 
one-step RT-PCR kit (Qiagen) and custom primers. 
mTR expression was monitored using the following 
primers: sense (mTR, +1) 5’-CGTAATACGACTCAC 
TATAGGGT-3’ and antisense (mTR, +451), 5’-
GCATGTGTGAGCCGAGTCCT-3’ as described else-
where [56].  The mTERT spliced variants were detected 
with the following primers [56]: sense, 5’-GCCTGA 
GCTGTACTTTGTCAA-3’, and antisense, 5’-CGCA 
AACAGCTTGTTCTCCATGTC-3’.  As a positive con-
trol we amplified the glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was amplified with the 
following primers: sense, 5'-ACCACAGTCCATGCCA 
TCAC-3' and antisense, 5'-TCCACCACCCTGTTGCT 
GTA-3'.  PCR products were separated by 2% agarose 
or in 4-20% gradient non-denatured PAG electro-
phoresis and were visualized with ethidium bromide. 
All RT-PCR data was analyzed digitally by Kodak 1D 
3.5 software. The net intensity of RT-PCR bands for the 
full-length mTERT and mTR were measured and 
normalized by net intensity of GAPDH bands. 
 
Chromatin immunoprecipitation (ChIP). ChIP assays 
were performed using the antibody against mouse Sp1 
(Upstate Biotechnology) or rabbit immunoglobulins as 
negative controls (Sigma) and ChIP assay kit (Upstate) 
on primary mouse keratinocytes as previously described 
[53, 54].  The proteins bound to DNA were cross-linked 
using 1% formaldehyde for 10 min at 37°C and the 
protein-DNA complexes were precipitated with a 
primary antibody against Sp1. After reversal of the 
cross-links and DNA recovery, the latter was used as a 
template to amplify the mTERT-derived Sp1 promoter 
region using the following primers: sense, 5’-CTCA 
CTGTCTGTGCAACCACAGCAGCTG-3’ (position-
363), and antisense, 5’-AGAGCACCGCGGGGCAA 
CGAGGAGCGCG-3’ (position +143) producing a 506 
bp PCR product. The PCR products were run on 2% 
agarose gels and visualized by ethidium bromide. 
 
Senescence-associated β-galactosidase (S-β-gal) activity. 
Mouse keratinocytes were transfected with shRNA for 
72 h or treated with Sirtinol for 24 h prior to assaying. 
The S-β-gal activity was measured using a senescence 
kit (Cell Signaling). Briefly, the cells were fixed with 
3% formaldehyde solution [29]. The cells were then 
washed and incubated with staining solution (1 mg/l, 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-
gal), 40 mM citric acid/sodium phosphate buffer, pH 
6.0, 5 mM ferrocyanide, 5 mM ferricyanide, 150 mM 
NaCl, and 2 mM MgCl2) for 12–18 h to visualize S-β-
gal activity as described [52].  Data were plotted as ratio 
of senescent cells over total cells using Microsoft Excel 
software. All of the data (mean +SD) were from at least  
three independent experiments. 
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